Objective: This study describes the safety and midterm efficacy of a noncovered stent-assisted embolization (SAE) technique in treating patients with wide-base renal artery aneurysms (RAAs).
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However, angiographic studies have indicated a higher incidence rate of 2.5% in hypertensive patients. 2 The clinical symptoms include flank pain and tenderness, hypertension, hematuria, and even hypovolemic shock. Most patients with RAA are asymptomatic, and almost all are diagnosed by routine physical examination. The rupture of an RAA can lead to hemorrhage and renal function impairment. The risk factors for rupture of RAAs include large size (diameter >20 mm), expansion, and pregnancy. 3 An aneurysm of diameter >20 mm is considered suitable for surgical treatment by most surgeons. Surgical managements of RAAs include open surgery and endovascular techniques such as transcatheter embolization and stenting. The elimination of surgical trauma, potential decreased morbidity, and faster recovery make endovascular repair an attractive alternative treatment. Morphology and location of the aneurysm along the renal artery are the main determinants of surgical treatment choice. 4 RAAs with a complex anatomy, including unfavorable base or sac ratio, can be hardly treated by traditional endovascular methods. The classification of RAAs is always according to their shape, location, and wall. Saccular aneurysms may be arbitrarily classified as narrow or wide base according to the diameter of the entry portal from the parent vessel to the aneurysm sac. Noncovered stent-assisted embolization (SAE) as an endovascular remodeling technique has been used for the treatment of intracranial aneurysms with complex anatomy. 5 Our purpose for this study, after a thorough review of our experience of noncovered stent-assisted coiling embolization for treatment of RAAs, was to gain insight into the advantages and limitations of the application of noncovered stent-assisted coiling embolization and develop a scientific approach for the most optimal treatment choice for RAAs.
METHODS
This study was approved by the Changhai Hospital Medical Ethics Committee, and written informed consent was obtained from all participants. The endovascular procedure performed in our study was in accordance with the current guidelines on peripheral artery disease. 6 Inclusion criteria and patient characteristics. RAAs were defined as focal, isolated dilatation of all three layers of the arterial wall that measured >1.5 times the diameter of the normal proximal adjacent arterial segment. Between February 2011 and June 2014, 114 consecutive patients with RAAs verified by computed tomography angiography (CTA) were treated at our institution, Changhai Hospital, Second Military Medical University, Shanghai, China (Fig 1) . The indications for hospital intake usually were low back pain, refractory hypertension, RAAs $2 cm, or progressive aneurysmal dilatation of the renal artery. Aneurysms with relevant branches perfusing a significant portion of the kidney and patients with limited economic conditions would be treated by open surgery. Open surgery was performed in 11 patients, and s ix patients required medicine for treatment.
Endovascular repair was offered to 97 patients. Aneurysms presenting with a wide base or involving bifurcations, with possible subsequent exclusion of more than one branch, were included for this type of treatment. Exclusion criteria for this type of endovascular treatment were the presence of aneurysms without an adequate neck for catheterization or without optimal proximal and distal landing zones when stent placement was planned, the presence of significant tortuosity of the target vessel, all of the contraindications to the use of iodinated contrast medium, and fusiform aneurysms.
The three main endovascular operation methods to treat RAA are covered stent exclusion, coil embolization, and noncovered-stent assist coil embolization. Twentyeight eligible patients were acceptable candidates for treatment with noncovered stent-assisted coil embolization following the technique described in this report. No limitations were placed on the number of aneurysms and vessels to be treated.
Baseline measurements. The symptomatic RAA is defined as difficult-to-control hypertension, flank pain, hematuria, abdominal pain, and other pain (back pain, etc). CTA was used to evaluate the renal arteries, and three-dimensional reconstruction was obtained with Aquarius software (TeraRecon, Foster City, Calif). Status of patency or thrombosis of the aneurysms was assessed using delayed-phase imaging.
Blood pressure was obtained from patients seated in a chair after at $5 minutes of rest. Blood pressure was measured twice, and the average of the two values was recorded. Hypertension was defined as systolic blood pressure $140 mm Hg or diastolic blood pressure $90 mm Hg, or both. Patients with hypertension who took oral antihypertensive medications before being hospitalized stopped the antihypertension therapy after they were hospitalized and did not take any medicine to control blood pressure during follow-up. The serum creatinine concentration and glomerular filtration rate (GFR) were obtained from all patients before and after the operation. GFR was used as an index of kidney function and was calculated using the isotope dilution mass spectrometry- GFR was assessed preoperatively and postoperatively at 1, 6, and 12 months and at the last follow-up.
Selection of endovascular prosthesis. The diameter and length of the stent was determined by information derived from the CTA and intraoperative aortography with calibrated catheters. All of the stents used in our study were self-expanding stents: Solitaire FR (eV3 Endovascular, Inc, Plymouth, Minn), Express2 (Boston Scientific, Natick, Mass), and PALMAZ BLUE (Cordis, Miami Lakes, Fla) were used. According to the diameter of the RAA, the 0.018-inch or 0.035-inch Interlock Fibered IDC Occlusion System (Boston Scientific) was chosen for filling the RAA. Endovascular procedure. After the patient provided informed consent, the embolization was performed with local anesthesia via transaxillary access or transfemoral approach. A dose of clopidogrel (75 mg daily) and aspirin (100 mg daily) was administered orally immediately after a decision was made to perform noncovered stent-assist coil embolization for the treatment of RAAs.
Systemic heparinization was given at the beginning of the procedure, aiming for an increase of the activated clotting time to a level of two to three times over baseline. For the endovascular intervention, the main renal artery was first catheterized with 6F flexible, long-sheath introducer (Flexor Check-Flo Introducer; Cook Medical, Bloomington, Ind). A 300-cm-long 0.014-inch Transend guidewire (Boston Scientific) was navigated under roadmapping fluoroscopy control from the main artery into the posterior segmental renal artery. A detachable, Solitaire bare-metal stent was placed over the aneurysm base extending to the distal branch. If the RAA located at the bifurcation of the main renal artery where renal artery access was insufficient to provide complete reconstruction of the renal artery bifurcation, we needed to introduce into a new sheath introducer (Flexor Check-Flo Introducer) for kissing stents with another Solitaire bare-metal stent. Because patients had good vascular compensation, both stents were minimally oversized relative to the treated artery.
ARTICLE HIGHLIGHTS
Although placing two 6F sheaths was difficult, the trunk renal artery was able to accommodate two 6F sheaths. The 6F sheath's inner diameter is 2 mm, and we placed two 6F sheaths in the renal artery, so the stent catheter and microcatheter could fit. The outer diameter of the stent used is 0.021 inches (0.5 mm) before release. A 2.4F microcatheter (Renegade STC 18; Boston Scientific) was previously left at the aneurysm sac through the same renal arteries sheath before the stent deployed or carefully advanced with a guidewire through the stent mesh into the aneurysm. The aneurysm was filled with platinum detachable microcoils (Interlock Fibered IDC Occlusion System).
Stents and coils were deployed according to standard procedure, as recommended by the manufacturer. Two different stent placement strategies were used in this series: (1) stent placement was achieved before coil placement, which means that the stent was implanted first to bridge the wide aneurysm base, followed by coil placement; and (2) stent placement was achieved after coil placement, which means that some or part of the coils were introduced into the aneurysm sac before the stent was implanted. In most cases we placed the stent first. However, we placed coils first when the aneurysms located in the branch artery or the base/sac were <70% and the parent artery diameter was thin. The immediate angiographic results were evaluated. Free blood flow to the distal arterial branches was confirmed by repeated angiography during the intervention.
To reduce thrombosis risk of the branch artery stent in some patients who might be insensitive to aspirin and antiplatelet therapy, termed antiplatelet-therapy resistant, we routinely administered low-molecularweight heparin, combined with antiplatelet therapy, immediately after the procedure (40 mg every 12 hours for 3 days by means of subcutaneous injection). Puncture site bleeding and other bleeding risk did not increase after these treatments. All patients were maintained by means of aspirin (100 mg daily) and clopidogrel (75 mg daily) for 1 year, followed by a 100-mg dose of aspirin daily.
Follow-up. All patients underwent follow-up at 1, 6, and 12 months, and every 12 months thereafter. Patients were interviewed by telephone every month. CTA was obtained to assess the RAA morphology and parent artery patency at 1, 6, and 12 months, and then every 12 months thereafter. Additional CTA or digital subtraction angiography examination was performed if the patients demonstrated new symptoms or signs of adverse events. Blood pressure and serum creatinine concentrations were also measured in all patients, and the GFR was calculated for assessment of adverse events and medication changes.
Clinical success was defined as complete shrinkage or stabilization of an aneurysm without complications. Minor perioperative complications included wound infection, urinary tract infection, urinary retention, minor renal infarct, and transient renal insufficiency, which means the patients' renal function can recover on its own without dialysis. Major perioperative complications included multisystem organ failure, myocardial infarction, and renal failure requiring dialysis. Late postoperative complications included persistent abdominal abscess, stent stenosis, renal bypass thrombosis, renal artery thrombosis, and postembolization syndrome, which is defined as a combination of fever, leukocytosis, 
RESULTS
Patient characteristics. This retrospective, consecutive series included 28 RAA patients (64% female) refractory to endovascular treatment with covered stent exclusion or coil embolization. Noncovered stent-assisted coil embolization was used to treat these patients. The mean age of the patient cohort was 49 6 10 years, the mean body mass index was 22 6 2 kg/m 2 , and 61% had hypertension. Two patients had coronary artery disease, and one patient each had atrial fibrillation, renal inadequacy, and peripheral arterial disease. There were three patients with diabetes mellitus and four patients with smoking history. Most of the patients were asymptomatic (79%). Six patients were diagnosed with fibromuscular dysplasia (Table I) .
Anatomic characteristics and indication. This study focused on the 34 aneurysms in 28 individuals who were treated with noncovered stents and coil embolization. Among 28 RAA patients, mean aneurysm diameter was 22.4 6 10.3 mm. The average base width was 15.7 6 7.4 mm, and the mean sac/base ratio was 0.7 6 0.1. The typical images of RAA are shown in Fig 2. There were 34 aneurysms in the 28 patients, with 3 aneurysms in 1 patient, 2 in 4 patients, and 1 in 23 patients. The location of the aneurysm was the hilus in 12 patients, proximal portion in 7, middle portion in 3, and branch in 12. Most patients were type I (71%) according to the Rundback classification. 8 The characteristics of the aneurysms are summarized in Table II .
Safety. The mortality was 0%, and no parent artery occlusion was found during follow-up. There were no acute procedural adverse events. There were, however, several endovascular surgery complications, including a femoral pseudoaneurysm (1 patient) and minor renal infarct (1 patient). One patient required dialysis for renal failure that developed 1 month after surgery. During repeat CTA at 6 months postoperatively, one patient with stent stenosis underwent reintervention by angioplasty. The primary patency at 1, 6, and 12 months was 100%, 96%, and 100%, respectively, and primary assisted and secondary patency were 100%.
Follow-up results. The baseline systolic and diastolic blood pressure were 136 6 21 mm Hg and 82 6 9 mm Hg, respectively, and they significantly decreased to 125 6 8 mm Hg and 70 6 4 mm Hg, respectively, at the 12-month follow-up. Serum creatinine (from baseline values 81.2 6 30.6 mmol/L to 60.8 6 5.7 mmol/L at the 12 month follow-up; P < .001) was significantly decreased and GFR (from baseline values 88.8 6 25.9 mL/min/ 1.73m 2 to 105.9 6 15.9 mL/min/1.73m 2 at the 12 month follow-up; P < .001) was significantly increased at the 6 and 12 month assessments compared with the baseline. Presurgery CTA showed a baseline mean aneurysm maximum diameter of 22.4 6 10.4 mm and an average aneurysm sac thrombosis ratio (the ratio between thrombus volume of aneurysm and the whole volume of aneurysm) of 17.3% 6 6.9%. The mean aneurysm maximum diameter of patients was 21.8 6 9.9, 19.5 6 8.7, and 17.5 6 7.9 mm at 1, 6, and 12 months, respectively, without a significant difference. However, the aneurysm sac thrombosis ratio was obviously increased at 1 (63.9 6 11.1), 6 (88.7 6 7.0), and 12 months (97.8 6 3.9) of follow-up (Fig 3) . Complications occurred in four patients during follow-up, including 1 major, 2 minor, and 1 late complication, for a complication incidence rate of 14.3% (Fig 4) .
DISCUSSION
With the introduction of SAE, wide-based RAAs that typically required open surgery could be treated through an effective and minimally invasive approach. This study demonstrated that noncovered stent-assisted coil embolization is safe and effective in patients with widebased RAAs. In addition to absence of acute procedural complications, the follow-up data indicated one patient had a long-term complication. A significant decrease in blood pressure was seen in all patients at 1 and 6 months of follow-up. A statistically significant improvement was observed in renal function, as determined by serum creatinine and GFR, at 1 and 6 months after the operation.
SAE has been widely used for treating aneurysms in the abdomen and pelvis, especially intracranial aneurysms. [9] [10] [11] [12] [13] Angiographic and clinical outcomes in these studies indicated that SAE was safe and effective in curing intracranial aneurysms, especially wide-base aneurysms and those at complicated locations. Similarities in the morphology of intracranial aneurysms and renal aneurysms create common links in the therapy process.
Open and endovascular surgery were the two treatment methods for RAA. Tsilimparis However, coil embolization of the first-and secondorder branch aneurysms is often associated with distal parenchymal loss, and current stent graft technology prohibits use of these endoprostheses in the branch renal arteries. SAE as a therapeutic choice for RAA has been previously reported. 17, 18 Similar to intracranial aneurysms, SAE was also the preferred treatment for aneurysms with a wide base and located in branch artery. 14, 19 However, as a result of the low morbidity of RAA, the treatment indication and effect of SAE on RAA remains largely unknown. RAAs can be classified according to their shape (saccular and fusiform), location (extra-and intraparenchymal) and wall (dissection and nondissection). 20 Depending on the diameter of the entry portal from the parent vessel to the aneurysm sac, saccular aneurysms may be arbitrarily classified as narrow or wide based. Rundback et al 8 combined the classifications to divide the RAAs into three main therapeutic types: type I, sacculardsacs arising from the main renal artery trunk; type II, fusiform or sacculardarising from a proximal bifurcation; and type III, intralobar aneurysmsdarising from small segmental or accessory arteries. The RAAs in the patients included in our study were type I in 70.6%, type II in 0.0%, and type III in 29.4%. The average diameter of the aneurysms was 22.4 6 10.3 mm. All aneurysms were located in the main renal artery trunk, and the diameter of aneurysm was >20 mm, which is preferentially considered for treatment. Our treatment of branch RAAs was based on two considerations. First, if the patients had symptoms, such as low back pain or refractory hypertension, branch RAAs of any diameter should be treated. Second, an aneurysm with a diameter of $2 cm or 1.5-times larger than the diameter of the branch renal artery should be treated. The average base width was 15.7 6 7.4 mm, and average ratio between the diameter of saccular and the base was 70% 6 8%. A wide-neck RAA has been defined as a base opening >70% of the aneurysm diameter. 21, 22 Our experience, in accordance with previous report, suggests that endovascular therapy for wide-based RAA with coil embolization alone may lead to inadequate saccular obstruction and coil migration to distal arteries. 23, 24 In most cases, we placed the stent first because the stent is deployed to cover the aneurysm neck, gently securing the coil mass within the aneurysm sac. However, when the aneurysm located in the branch artery or the base/sac ratio was <70% and the parent artery diameter was thin, we placed coils first to prevent stent motion or migration during deployment. Moreover, endografts offer the advantage of completely excluding the base of the aneurysm but show high incidence of glomerular filtration rate (GFR), (E) aneurysm maximum diameter, and (F) aneurysm sac thrombosis ratio changes from presurgery to 1, 6, and 12 months. A and B, Decreases are shown in mean systolic and diastolic blood pressure, as determined by 24-h ambulatory blood pressure monitoring at 1, 6, and 12 months compared with re-surgery. C and D, Serum creatinine was significantly decreased at 6 and 12 months compared with preoperatively, and the GFR was significantly increased. E, Aneurysm maximum diameter showed no significant difference. F, Significant improvements of aneurysm sac thrombosis ratio were found at 1, 6, and 12 months compared with preoperatively. The horizontal line in the middle of each box indicates the median; the top and bottom borders of the box mark the 75th and 25th percentiles, respectively, and the whiskers above and below the box show the range. *P < .05.
Fig 4.
Kaplan-Meier analysis of the complication incidence rate.
endoleaks and risk of occluding functional branch vessels, leading to renal infarction in the type II and type III RAAs. 22 Open surgery was the only option for treating such aneurysms in the past. However, the endovascular method is an attractive alternative because of its low complication rate and the possibility of repeating the procedure in case of incomplete exclusion. With the development of materials and technology, SAE can be perfectly used for the treatment of RAA, especially wide-based, and type II and type III RAAs.
The endovascular method was first used for treating RAAs in 2001, and SAE was introduced to treat RAAs in 2006. 20, 25, 26 Some reports compared the outcomes between open surgery and endovascular repair of RAA. 14, 16, 19 In addition to the advantages of endovascular repair, there was no difference in decline in renal function between open and endovascular repair. 14 However, few patients treated with SAE were included in these reports. We performed a retrospective evaluation of 28 RAA patients treated with SAE. RAA was reported to be associated with hypertension in 73% of cases. 26 In our opinion, hypertension and renal function were caused by renal artery ischemia. An RAA always leads to the vascular compression and might cause a change in renal hemodynamics. Our research found that SAE significantly reduced blood pressure at 1, 6, and 12 months after the surgery. The blood pressure of all patients was within the normal limits during the follow-up. Renal function was evaluated by serum creatinine and GFR. In this study, the aneurysm maximum diameter decreased by an average of 4.9 mm during the 12-month follow-up in the entire cohort, but the difference was not significant. It might be because the coils fixed the diameter of the aneurysm. However, the aneurysm sac thrombosis ratio was obviously increased. Our results indicated that SAE cannot immediately improve renal function. But during the follow-up, especially at the 6-month follow-up, average serum creatinine was significantly decreased, and the average GFR was remarkably increased. These findings indicate that SAE is an effective method for treating RAA and has a short-term effect in improving blood pressure and renal function.
Despite observing a statistically significant blood pressure reduction and renal function improvement, important limitations of this study were the small sample size, the possibility of observer bias in recording of blood pressure, and a lack of information on split renal function and other factors that may have influenced the renal function during follow-up. Despite these limitations, our study demonstrated the SAE treatment effect for RAA and showed a clinically relevant difference in RAA patients during the follow-up. A randomized controlled trial with a large sample size and a double-blind design is necessary to definitively establish the efficacy of SEA in RAA.
CONCLUSIONS
SAE can be safely and effectively performed in patients with a wide base or branch artery RAA. It showed a midterm reduction of blood pressure and improvement of renal function. This study provides a scientific basis for use of SAE for endovascular treatment of RAA with a wide base or branch location. It has widened the range of endovascular applications in RAA therapy. 
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